RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q1 2024
Top Holdings69 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ROCKET PHARMACEUTICALS INC | 17.7M | $476.5M | 7.0% | $18.79 | +43.35% | 21 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 6M | $391.3M | 5.8% | $43.05 | +50.98% | 13 qtrssince 2021-Q1 | Decreased 0 |
AXSOME THERAPEUTICS INC | 4.5M | $358.5M | 5.3% | $61.43 | +29.90% | 21 qtrssince 2019-Q1 | Increased 60 |
Ultragenyx Pharmaceutical, Inc. | 7.1M | $330.9M | 4.9% | $52.92 | -11.77% | 10 qtrssince 2021-Q4 | Increased 59 |
BRUKER CORP | 3.3M | $314.1M | 4.6% | $72.62 | +28.40% | 5 qtrssince 2023-Q1 | Unchanged 0 |
ARGENX SE - ADR | 667,195 | $262.7M | 3.9% | $348.48 | +12.98% | 21 qtrssince 2019-Q1 | Unchanged 0 |
ACADIA Pharmaceuticals Inc. | 13.8M | $255.7M | 3.8% | $18.35 | +0.77% | 8 qtrssince 2022-Q2 | Increased 68 |
NATERA INC | 2.6M | $237.2M | 3.5% | $42.12 | +117.17% | 19 qtrssince 2019-Q3 | Unchanged 0 |
PTC THERAPEUTICS INC | 7.4M | $216M | 3.2% | $43.39 | -32.95% | 21 qtrssince 2019-Q1 | Unchanged 0 |
MASIMO CORP | 1.5M | $214.8M | 3.2% | $174.28 | -15.74% | 21 qtrssince 2019-Q1 | Unchanged 0 |
| 8M | $203.4M | 3.0% | $24.04 | +6.15% | 16 qtrssince 2020-Q2 | Increased 66 | |
MERUS N V | 4.1M | $185M | 2.7% | $33.69 | +33.66% | 4 qtrssince 2023-Q2 | Increased 78 |
CYTOKINETICS INC | 2.5M | $177M | 2.6% | $27.00 | +159.64% | 15 qtrssince 2020-Q3 | Unchanged 0 |
APOGEE THERAPEUTICS INC | 2.5M | $164M | 2.4% | $27.25 | +143.88% | 3 qtrssince 2023-Q3 | Increased 60 |
ALKERMES PLC | 6.1M | $163.9M | 2.4% | $27.54 | -1.71% | 3 qtrssince 2023-Q3 | Increased 74 |
PROTAGONIST THERAPEUTICS INC | 5.3M | $153.8M | 2.3% | $22.38 | +29.24% | 19 qtrssince 2019-Q3 | Unchanged 0 |
PENUMBRA INC | 675,888 | $150.8M | 2.2% | $262.16 | -14.87% | 11 qtrssince 2021-Q3 | Increased 53 |
| 8.8M | $148.6M | 2.2% | — | — | 18 qtrssince 2019-Q4 | Increased 64 | |
AKERO THERAPEUTICS INC | 5.4M | $137.2M | 2.0% | $24.00 | +5.26% | 2 qtrssince 2023-Q4 | Increased 72 |
ESTABLISHMENT LABS HLDGS INC | 2.7M | $136.2M | 2.0% | $26.73 | +90.43% | 21 qtrssince 2019-Q1 | Increased 56 |
RTW INVESTMENTS, LP manages $6.8B across 69 positions as of Q1 2024. Top holdings: RCKT (7.0%), IMCR (5.8%), AXSM (5.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 15 new positions, 10 exits, 25 increased. Top move: MRUS (INCREASED, conviction 78). Portfolio: $6.8B across 69 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer